门户生物科技为开发世界上第一个全长单分子蛋白质定序器提供了35M美元。 Portal Biotech secures $35M to develop world's first full-length single-molecule protein sequencer.

总部位于伦敦的生物技术公司 Portal Biotech 在 A 轮融资中获得了 3500 万美元，这是欧洲最大的生命科学工具公司融资之一。 Portal Biotech, a London-based biotech company, secured $35 million in a Series A funding round, one of Europe's largest for a life sciences tools firm. 这项投资将有助于开发世界上第一个全长单分子蛋白质定序器,有可能改变药物发现和精密医学。 The investment will help develop the world's first full-length single-molecule protein sequencer, potentially transforming drug discovery and precision medicine. 北约创新基金和 " 早鸟风险资本 " 在各种现有和新投资者的额外支助下,共同领导了这一捐款过多的回合。 NATO Innovation Fund and Earlybird Venture Capital co-led the oversubscribed round, with additional support from various existing and new investors. 这些资金还将扩大该公司的研究、工程和数据科学团队。 The funds will also expand the company's research, engineering, and data science teams.